Abilify Discmelt and Lorcaserin Extended-Release Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using lorcaserin together with ARIPiprazole may increase the risk of a rare but serious condition called the neuroleptic malignant syndrome, which may include symptoms such as agitation, confusion, delusion, hallucination, extreme changes in blood pressure, excessive sweating, fever, shivering or shaking, restlessness, muscle spasm or stiffness, tremor, and incoordination. Severe cases may result in coma and even death. You should contact your doctor immediately if you experience these symptoms while taking the medications. In addition, both lorcaserin and ARIPiprazole, especially when given long-term, can cause increases in the levels of a hormone called prolactin. The health effects of high levels of prolactin are not known; however, some patients (including men) have experienced increased breast size and milk or milky discharge from the breasts. Some breast cancers may also be dependent on prolactin; therefore, let your doctor know if you have a history of breast cancer. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Lorcaserin is a serotonergic drug. Potentially life-threatening neuroleptic malignant syndrome (NMS)-like reactions have been reported during use of serotonergic drugs and antipsychotics or other dopamine antagonists. The safety of lorcaserin when coadministered with antidopaminergic agents has not been systematically evaluated and has not been established.

MONITOR: Lorcaserin can cause elevations in prolactin, which may be additive to the hyperprolactinemic effects of dopamine antagonists. In clinical trials of at least one year duration, elevations of prolactin greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal occurred in 6.7%, 1.7%, and 0.1% of lorcaserin-treated patients, compared to 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively. One patient treated with lorcaserin developed a prolactinoma. Although elevated serum prolactin levels have been associated with reports of amenorrhea, galactorrhea, gynecomastia and impotence, the clinical significance of hyperprolactinemia is unknown for most patients. Long-standing hyperprolactinemia may lead to low levels of estrogen and increased risk of osteoporosis. In rodents, an increase in mammary neoplasms has been found after chronic administration of prolactin-stimulating neuroleptic drugs. However, clinical and epidemiologic studies conducted to date have not established a causal relationship.

MONITOR: Coadministration with lorcaserin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6, including many neuroleptic agents and phenothiazines. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by lorcaserin. In a study consisting of 21 CYP450 2D6 extensive metabolizers, administration of the probe substrate dextromethorphan in combination with lorcaserin 10 mg twice daily for 4 days increased dextromethorphan peak concentrations (Cmax) by approximately 76% and systemic exposure (AUC) by approximately 2-fold. A dosage adjustment may be necessary for CYP450 2D6 substrates following the initiation or discontinuation of lorcaserin.

MANAGEMENT: Caution is advised when lorcaserin is prescribed in combination with antipsychotics or other antidopaminergic agents (e.g., droperidol, domperidone, metoclopramide, phenothiazines, tetrabenazine). Clinicians, caregivers, and family members should be apprised of the risk of neuroleptic malignant syndrome and be alert to potential signs and symptoms such as mental status changes (e.g., mutism, catatonia, stupor, coma, agitation, confusion, hallucinations, delusions), autonomic instability, restlessness, rigidity, ataxia, myoclonus, hyperreflexia, tremors, diaphoresis, elevated creatine phosphokinase levels, and hyperpyrexia. If NMS is suspected, treatment with these agents should be discontinued immediately and emergency medical attention sought. Prolactin levels should be measured when there are signs and symptoms of prolactin excess such as galactorrhea or gynecomastia. Consideration should be given to discontinuation of prolactin-stimulating drugs including lorcaserin.

Abilify Discmelt

Generic Name: aripiprazole

Brand name: Abilify, Abilify Discmelt, Abilify Maintena, Aristada, Abilify MyCite, Aristada Initio

Synonyms: n.a.

What is Abilify Discmelt?

Lorcaserin Extended-Release Tablets

Generic Name: lorcaserin

Brand name: Belviq, Belviq XR

Synonyms: Lorcaserin

What is Lorcaserin Extended-Release Tablets?